Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disorder Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC1A4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC1A4 Extracellular Loop (ECL)-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View SLC1A4 Products |
| Gene Delivery | SLC1A4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Native 10-TM conformation preservation. |
View SLC1A4 Products |
| Benchmark Ab | Anti-SLC1A4 Recombinant Antibody Recombinant positive control for binding and validation assays. |
View SLC1A4 Products |
| Validator | SLC1A4 siRNA Set For target knockdown and specificity verification. |
View SLC1A4 Products |
| Related Target A | SLC1A5 Closely related homolog (ASCT2). Crucial for counter-screening to ensure drug selectivity. |
View SLC1A5 Products |
| Related Target B | SLC7A5 LAT1 amino acid transporter. Synergistic metabolic target in cancer cell proliferation. |
View SLC7A5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation Retention (10-TM structure) | Lentivirus Premade Particles for stable cell line generation, ensuring native membrane folding. |
| Homology Counter-Screening (SLC1A5 cross-reactivity) | High-purity recombinant SLC1A5 and SLC1A4 ECL-Fc proteins for precise selectivity assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as recombinant positive controls. |
| False Positives in Screening | Sequence-validated siRNA sets included for target-specific knockdown validation. |
Live SLC1A4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC1A4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors and antibody-drug conjugates (ADCs) targeting metabolic vulnerabilities in cancer. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective inhibition of SLC1A4 over its close homolog SLC1A5 to minimize off-target toxicity in the central nervous system and peripheral tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules | Academic Institutions, Biotech Startups | Glioma, Solid Tumors, Neurological Disorders | High-throughput transport assays (Need Lentivirus for stable cell lines) |
| Monoclonal Antibodies | Oncology-focused Biopharma | Breast Cancer, Colorectal Cancer | Epitope mapping & binding affinity (Need ECL-Fc recombinant proteins) |
| ADCs | Next-gen Biologics Developers | Refractory Solid Tumors | Internalization assays (Need high-purity antigens and stable cell lines) |